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Abstract
Neuroinflammation plays an important role in the pathogenesis of a range of brain disorders.
Non-invasive imaging of neuroinflammation is critical to help improve our understanding of
the underlying disease mechanisms, monitor therapies and guide drug development. Gen-
erally, MRI lacks specificity to molecular imaging biomarkers, but molecular MR imaging
based on chemical exchange saturation transfer (CEST) can potentially detect changes of
myoinositol, a putative glial marker that may index neuroinflammation. In this pilot study we
aimed to investigate, through validation with immunohistochemistry and in vivo magnetic
resonance spectroscopy (MRS), whether CEST imaging can reflect the microglial response
to a mild inflammatory challenge with lipopolysaccharide (LPS), in the APPSwe/ PS1
mouse model of Alzheimer’s disease and wild type controls. The response to the immune
challenge was variable and did not align with genotype. Animals with a strong response to
LPS (Iba1+, n = 6) showed an increase in CEST contrast compared with those who did not
(Iba1-, n = 6). Changes of myoinositol levels after LPS were not significant. We discuss the
difficulties of this mild inflammatory model, the role of myoinositol as a glial biomarker, and
the technical challenges of CEST imaging at 0.6ppm.
Introduction
Neuroinflammation is a potential factor in a range of neurodegenerative diseases, including
stroke, Parkinson’s and Alzheimer’s disease (AD) [1–3]. Microglia, key mediators of the CNS
response to an inflammatory stimulus [4], react to pathological insults by undergoing a trans-
formation towards an activated state, changing morphology, accumulating at the site of the
inflammatory insult, and triggering the cascade of molecular events that characterizes neuroin-
flammation. In the healthy brain, this process is finely regulated, but in pre-existing neurode-
generative conditions the microglial response can exacerbate disease progression [5, 6].
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Therefore, glial activation and neuroinflammation are potentially key modifiable mechanisms
for different neurodegenerative disorders.
Non-invasive imaging biomarkers are important tools for the development of potential
new treatments and for monitoring therapeutic effects. Radiolabeled ligands for positron emis-
sion tomography (PET) based on the upregulation of the translocator protein 18kDa (TSPO)
have been shown to allow detection and monitoring of neuroinflammation [7, 8]. Due to its
versatility, absence of ionizing radiation and routine clinical use, MRI would be a particularly
attractive modality to complement PET to image neuroinflammation non-invasively. To date,
however, MR imaging is generally not sensitive enough to monitor molecular markers of
neuroinflammation.
MR spectroscopy on the other hand allows to measure a range of metabolites that have
been linked to glial activation and neuroinflammation, including creatine, choline, glutamate,
and myoinositol (mI) [9–11]. But the spatial resolution of MR spectroscopy is poor, and an
MR imaging approach that retains spatially resolved molecular information indicative of neu-
roinflammation would be highly valuable. One way of overcoming the limitation of MR spec-
troscopy while to a degree retaining its specificity is to use chemical exchange saturation
transfer (CEST), where proton exchange between low-concentration molecules—below the
detection threshold of standard MRI—containing hydroxyl (-OH), amine (-NH2), or amide
groups with the abundant water protons amplifies the signal of a target molecule [12]. Several
studies have explored the possibility of imaging a neuroinflammatory response with CEST
MRI, focusing on strong inflammatory stimuli or inflammation in late stages of disease. A
reduction in CEST contrast at 3 ppm (attributed predominantly to glutamate changes and
hence named GluCEST) was seen to correlate with a decrease in glutamate levels in 18–20
month old animal models of AD [13]. Similar changes in the GluCEST signal have been dem-
onstrated in a model of astrocyte activation (overexpression of the cytokine ciliary neuro-
trophic factor, CNTF, a strong activator of astrocytes) [14]. A reduced GluCEST signal has
also been reported in a 20-month old mouse model of tauopathy [15], in a 12-month old
mouse model of Huntington disease [16] and in patients on the psychosis spectrum [17], while
increased gluCEST signal was observed in a mouse model of dopamine deficiency [18].
Myoinositol is primarily found in glial cells [9] and has therefore been proposed as a marker
for microglial activation [19]. An increase in myoinositol levels in MR spectroscopy studies
could be explained by a microglial proliferation observed in the neuroinflammatory response
[20–22]. Myoinositol is suitable for detection with CEST, because its six hydroxyl protons
exchange with bulk water at a rate of k = 600 s−1, and a frequency shift Δω< 1 ppm from bulk
water, placing it in the slow to intermediate NMR exchange regime. This was first demon-
strated by Haris et al. [23], who later also described an increase in the CEST signal at 0.6 ppm
in an 18–20 month old AD mouse model [13]. Higher concentrations of myoinositol in Alz-
heimer’s disease have also been demonstrated in the very early stages of disease progression
[24]. An increase in myoinositol levels has been consistently observed in the posterior cingu-
late, hippocampus and anterior cingulate gyrus in mild cognitive impairment in the early stage
of dementia [22]. Together these studies suggest that myoinositol levels assessed by MR spec-
troscopy may index neuroinflammation and microglial activation. However, recent studies
question the relationship between myoinositol and microglial activation. Datta et al. [25]
reported that MRS myoinositol levels were not associated with TSPO PET in Multiple Sclerosis
(MS) patients, and studies on Alzheimer’s disease have proposed that myoinositol levels might
be associated with amyloid plaque load instead of microglial activation [16, 26].
Administration of the neurotoxin lipopolysaccharide (LPS) is a standard approach to acti-
vate microglia through binding to the Toll-like receptor 4, which dose-dependently induces
secretion of inflammatory mediators [27]. Previously, we showed that a weak peripheral dose
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of LPS (1 mg/kg iv) led to a rise in myoinositol levels within four hours in an APP/PS1 model
of Alzheimer’s disease, but without microgliosis or morphological evidence of microglial acti-
vation [21]. This myoinositol increase was apparent in the APP/PS1 which failed to show a
microglial response to LPS, but not in wild type controls, which did show a microglial
response. This raised doubts whether myoinositol really was a glial marker in AD, as previ-
ously proposed by Murray et al. (25), but questions remain regarding the robustness of the
peripheral LPS challenge given the poor brain penetration of LPS [28]. Liu et al. reported
CEST measurements following LPS injections in subcutaneous tumors (after a 1 mg/kg direct
injection), but found no significant differences in the CEST signal one day after LPS adminis-
tration [29]. No study has set out to investigate whether CEST MRI could be used to visualize
changes following an LPS challenge directly in the brain.
In this pilot study we therefore aimed to explore whether CEST can detect the response to
LPS-induced microglia activation in APP/PS1 transgenics and wild type controls. We expected
that a challenge at a relatively low dose would be representative of the early inflammatory
response present in many neuroinflammatory disorders and it would lead to differential levels
of microglial activation in the AD model compared with wild-type (WT) controls. We further
hypothesized that CEST MRI would allow to distinguish between these responses. To explore
the origin of this CEST signal we measured a range of metabolite levels and in particular myo-
inositol measured by MR spectroscopy. Indeed, we found distinct responses of microglial acti-
vation through histology and CEST MRI could be used to differentiate them. However, the
LPS challenge was highly variable and separation between animals with and without responses
did not align with genotype.
Methods
Ethical statement
All procedures were approved as required under the UK Animals (Scientific Procedures) Act
1986 (Home Office project license number 40/3601). Data are reported according to the
ARRIVE guidelines for in vivo experiments [30].
Study design
Experimentally naïve female APPswe/PS1dE9 (APP/PS1) transgenic and wild-type C57BL6/J
(WT) mice were bred in the University Biomedical Service Unit (age: 3.0 ± 0.5 months old;
weight: 23.0 ± 0.6 g). They were maintained in individually vented (IVC) cages under standard
husbandry conditions on a 12/12 h light cycle, with lights on at 07:00 h; the room temperature,
relative humidity and air exchange were automatically controlled. Animals were group-housed
with ad libidum access to food and water, and provided with nesting material and a play tube.
Throughout the experiment, animals were kept under anesthesia with a mixture of oxygen
and isoflurane (Isocare, 3% for induction and 1–2% for maintenance). Animals were posi-
tioned in a stereotactic head frame and a small hole was made in the skull using Bregma as
reference at the following coordinates: - 2 mm anterior-posterior, 1.8 mm lateral (both hemi-
spheres), and 1 mm dorsoventral. Mice were given an intracerebral administration of lipopoly-
saccharide (LPS, 2 μL of 5 ng/μL) and phosphate buffered serum (PBS) contralaterally as
vehicle control, before being transferred to the MR imaging system. Injections were carried
out by two experimenters. MR experiments were carried out on a horizontal 9.4 T system (Agi-
lent, Palo Alto, California) with Vnmrj 4.0 software. A 22 mm volume coil (Rapid Biomedical
GmbH, Rimpar, Germany) was used for excitation and signal detection. Animals were posi-
tioned in the imaging system in a custom made frame to minimize movement. Eye gel
(Lubrithal) was applied in both eyes to avoid desiccation. Body temperature and breathing rate
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(80–120 breaths/min) were monitored and maintained stable throughout the experiment.
Brain metabolite levels were measured with MR spectroscopy, in two target volumes centered
over the injection sites in the hippocampus, first on the LPS side, then, with 0.5h delay on the
vehicle side where PBS was injected. Between the MRS scans, a CEST image was acquired with
the imaging plane covering the injection sites. MR spectroscopy scans acquired on the vehicle
(PBS) and LPS side were acquired 0.5h apart, so that the metabolite levels derived from the
MR spectra would be at equal interval from the CEST scan acquisition time. Three hours after
the start of the experiment mice were given an overdose of anesthesia, and brains were imme-
diately extracted and immersed in 4% paraformaldehyde (PFA) for further processing for
histology.
Drug treatment
10 ng lipopolysaccharide (LPS, Escherichia coli serotype, Sigma0111:B4, Sigma Aldrich, in
phosphate buffer saline) in 2 μL of PBS were administered through stereotactic direct injection
in the hippocampus, followed contralaterally by PBS as a vehicle control, using a 5 μL Hamil-
ton Neuros syringe (33 gauge Syringe, Sigma Aldrich).
MR spectroscopy acquisition
For positioning of the MRS voxels, a coronal anatomical scan was acquired with a Fast Spin
Echo Multi Slice (fsems) (RARE factor 8, TE = 11.8 ms, TR = 5 s, matrix size 256 × 256, field of
view, FOV 15 × 20 cm, 30 slices, slice thickness 0.5 mm)[31]. Two voxels of 8 mm3 were cen-
tered on the hippocampus, ipsilateral and contralateral to the injury. To optimize field homo-
geneity, shims were first adjusted with a global field map based shim (ge3dshim, Vnmrj 4.0),
followed by a local shim (FASTMAP)[32]. Shim quality was evaluated before every MRS acqui-
sition by measuring the signal full width half maximum (FWHM) of the water peak using a
LASER (localization by adiabatic selective refocusing) sequence without water suppression
[33]. Shims were further adjusted if necessary. In vivo MR spectroscopy scans were acquired
from two cubic 8 mm3 voxel with a LASER sequence (TR/TE = 2500/24 ms, 512 averages, 8
dummy scans, 4096 acquisition data points, spectral width 4006 Hz, acquisition time 22 min)
with VAPOR (variable pulse powers and optimized relaxation delays water suppression) [34].
A reference scan without water suppression was acquired for eddy current correction. To min-
imize motion artifacts and frequency drift, 512 averages were acquired in pairs of two and
aligned during post processing with the water peak as reference.
MRS data analysis
Data were analyzed using LCModel for estimation of metabolite concentrations [35]. The anal-
ysis window chosen was 0.2 ppm to 4 ppm. The signal was pre-processed with eddy current
correction, zero-order phasing, referencing and residual water line removal. Spectra were fit-
ted to a linear combination of 17 metabolites in a simulated basis set containing alanine,
aspartate, creatine, phosphocreatine, γ-aminobutyric acid, glucose, glutamine, glutamate, gly-
cerophosphorylcholine, phosphorylcholine, glutathione, mI, lactate, NAA, n-acetyl aspartatyl
glutamate, scyllo-inositol and taurine. Spectra were considered of sufficient quality if the line-
width reported by LCModel did not exceed 25 Hz. Metabolite concentrations derived from fit-
ted spectra consistently within Crame´r-Rao bounds < 10% were included in further analysis.
Relative metabolite concentrations were expressed as the ratio to total creatine. Across all spec-
tra, the average metabolite line width (full width at half maximum) was 12.9 ± 0.8 Hz, and the
signal to noise ratio was 8.9 ± 0.6, as reported by LCModel.
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CEST MRI acquisition
Each CEST experiment consisted of three scans: a reference image, a CEST image array and,
for B0 correction, a WASSR image array (water shift saturation referencing) [36]. CEST
parameters were optimized based on a simulation with a three-pool model of coupled Bloch
equations [37–39] using custom made software (MATLAB, The MathWorks Inc., Natick,
MA), and by in vitro experiments. For CEST presaturation, a 1.6 s hard pulse (0.9 μT) was
applied at 40 frequency offsets between ± 4 ppm at fixed intervals of 0.2 ppm. For image read-
out, a single-slice segmented gradient echo sequence with a Gaussian excitation pulse and cen-
tric encoding was acquired in two segments with 64 phase encoding steps each (FOV = 20 x 20
mm, slice thickness 2 mm, matrix size 128 x 128). The acquisition time for the CEST image
array was 6 min. The WASSR array consisted of a 0.5 s hard prepulse (0.1 μT), followed by the
segmented GE readout with 35 offsets in ±1 ppm (acquisition time 5 min). The reference
image was a single segmented GE acquisition without pre-saturation. In order to improve
magnetic field homogeneity, a 3% agarose gel filled the space between the top of the head and
the volume coil [40]. Shimming for CEST MRI was done using an automated 3D gradient
echo shim procedure (ge3dshim, Agilent). A linewidth < 30 Hz in the slice to be imaged was
deemed acceptable. Manual shims were used when required.
CEST image analysis
CEST images were analyzed with custom made software (Matlab, The Mathworks, Nattick,
MA). Images were thresholded, normalized and for each voxel, z-spectra were frequency-
interpolated using a spline method. WASSR frequency shift maps were derived with the maxi-
mum symmetry algorithm and used to correct CEST image arrays [36]. This resulted in a nor-
malized z-spectrum Msat/M0 and an asymmetry spectrum MTRasym, expressed in %:
MTRasym Doð Þ ¼ 100� ð
Msatð  DoÞ
M0
 
MsatðDoÞ
M0
Þ
where Msat is the MR signal intensity measured with the CEST sequence, M0 is the reference
signal intensity, and Δω the frequency shift.
CEST MTRasym values for each offset frequency were expressed as the average contrast in
1.25 x 1.25 mm regions of interest (ROI) drawn on a CEST map, one on each side covering the
LPS or PBS injection sites. The size and position of the CEST ROI was chosen to match those
for the quantitative analysis of the immunohistochemistry slides centered on the hippocam-
pus. The B0 homogeneity between LPS and vehicle was deemed sufficient for further analysis if
the frequency difference between the B0 measures in the LPS and vehicle ROI did not exceed
0.05 ppm.
Immunohistochemistry
Brains were fixed in 4% paraformaldehyde (PFA), stored at 4–8 ˚C for a minimum of 48
hours, and then embedded in paraffin wax on a tissue embedding station (Leica TP1020).
7 μm-thick coronal sections were cut throughout the hippocampus using a microtome (Micro-
tome Slee Cut 4060), mounted on APES coated slides and dried overnight at 40˚C. Immunos-
taining of Iba1 (ionized calcium binding adaptor molecule 1) was carried out as previously
described (26). Sections were first re-hydrated in consecutive rinses in xylene, 100% ethanol,
70% ethanol and dH2O and then immersed in sodium citrate buffer for 20 minutes at 95–99˚C
for antigen retrieval. Once the solution was cooled down to 70˚C, sections were washed in
PBS, incubated in 1% H2O2 solution to inhibit endogenous peroxidase activity, washed in PBS
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and blocked in 5% goat serum. Brain slices were then incubated with rabbit anti-Iba1 (Wako,
cat. nr. 019–19741; 1:6000 in PBS-T) antibody for 1h at room temperature, washed in PBS,
and incubated with biotinylated secondary antibody (Vectastain Elite ABC Kit, Rabbit IgG,
Vector Labs, Burlingame, CA cat. nr. PK-6101, 1:200 in PBS-T) for 30 min. Tissue was washed,
exposed to ABC-HRP (Vectastain Elite ABC Kit R.T.U, Vector Labs, cat. nr. PK-7100) and
labelled with DAB peroxidase substrate (Vector Labs cat. SK-4100) according to manufactur-
er’s instructions. Brain slices were then counterstained using a haematoxylin & eosin protocol,
dehydrated in increasing concentrations of alcohol and xylene for 2min, and mounted using
Clearvue mountant (Thermo Scientific, cat. nr. 4212). Digital focused photo-scanning images
were then acquired using a Hamamatsu NanoZoomer-XR 2.0-RS C10730 digital scanning
system with TDI camera technology a NanoZoomer (Hamamatsu Photonics K.K. Systems,
Japan) at 20x magnification and visualised using NDP.view2 (NanoZoomer Digital
Photography).
Semi-automated analysis of Iba-1 immunostaining
For extraction of morphometric features, we used our own custom made software [21, 41]. A
region of interest (ROI) was drawn on digitized histology images at 20x magnification, outlin-
ing the region covered by the CEST ROIs in the hippocampus (1.25 mm x 1.25 mm). Micro-
glial cell soma were first automatically identified by blurring with an average filter of adjacent
pixels and thresholding adapted for uneven background staining. Images were inspected and
corrected manually to avoid artifacts. This process provided the area occupied by glial cells
and isolated microglial processes and the soma size.
Experimental outcome measures and statistics
Primary outcome measures from CEST MRI were the MTRasym values from the LPS and PBS
side. Primary outcome measures from MRS were the normalized metabolite concentrations of
mI in the LPS and contralateral vehicle voxel. The visual inspection of activated microglia by
the pathologist was based on the number and morphology of Iba-1 stained microglial cells,
comparing cells in the hippocampus across both brain hemispheres. As confirmation of the
expert assessment, the difference in Iba-1 stained microglia soma size per slice was used as in
our previous study [21] as a morphometric marker of microglia activation known to be sensi-
tive to LPS [42, 43]. Data are presented as median (interquartile range) and were statistically
analysed using R (version 3.4.4) [44]. Boxplots represent the median, interquartile range and
outliers denoted by single points or whiskers. Outcome measures were compared between the
ROIs at the site of LPS injection and the contralateral ROI (PBS vehicle control) using both a
paired t-test and a nonparametric Wilcoxon rank sum test. Experiments and data analysis
were performed in blind.
Primary data are available on the Imperial College Research Data Repository, under 10.
14469/hpc/4127, while analysis tools are available for download on Github (https://github.
com/MariaICL/Paper_analysis_scripts).
Group sizes and exclusions
Of initially 17 mice in the pilot study, three were excluded from the analysis due to poor quality
of histological staining, which did not allow assessment of microglial morphology. MRS line-
width limits were exceeded in two animals, so their MRS data was excluded from final statis-
tics. One APP/PS1 animal showed a larger response on the vehicle side than the LPS side, and
one WT animal was injected outside the hippocampus in the striatum. Both are reported sepa-
rately. Table 1 summarizes the groups included in the analysis.
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Results
Microglial response to the inflammatory challenge
Histology was used to establish the response to the inflammatory challenge. All histological
images were examined in blind by an experienced, board certified pathologist. A highly vari-
able response was observed to the immune challenge, which could be readily distinguished in
two categories: those animals with strong activation of microglia [41] on the side where LPS
was administered (LPS Iba1+, n = 6, 3 WT, 3 APPSwe/PS1), and those who did not show a
response (LPS Iba1-, n = 6, 3 WT, 3 APPSwe/PS1), judged by the morphometry of the micro-
glial cells. One animal appeared to show higher activation in four of five slides on the PBS
injection side (PBS Iba1+, S1 Table) and is excluded from statistics and reported separately.
The qualitative assessment by the pathologist matched the independent quantitative assess-
ment of microglial activation when microglial soma size was measured.
In the Iba1+ group, Iba-1 immunostaining showed a strong localized microglial response to
LPS, which was higher compared with the contralateral side, where vehicle (PBS) only was
administered (Fig 1, S1 Fig). For Iba1+ the difference in soma size between the LPS vs the con-
tralateral PBS side was 10.1 μm2 (interquartile range: 6.8–15.5 μm2, p = 0.0041 paired t-test,
p = 0.0087 Wilcoxon rank sum test). For Iba1-, the difference was -7.5 μm2 (interquartile
range: - 9.6–0.7 μm2). No differences in classification in response to the stimulus were
observed between genotypes (Fisher exact test, p>>0.05). However, we observed a difference
with respect to the experimenter carrying out the intracerebral injection, and the Iba+ animals
were among the first to receive the LPS challenge (S1 Table). Injection sites were not visible in
T2 weighted images but could be identified in T2 maps. However, average T2 values did not
differ between the site of LPS and vehicle administration (S2 Fig).
Inflammatory response measured by CEST and MRS
We tested our hypotheses based on these categories (Iba1+, Iba1-); in particular, we hypothe-
sized that CEST at ~0.6 ppm is sensitive to the immune challenge, and that MRS of myoinosi-
tol is a marker of this activation.
CEST response to LPS is higher in Iba1+ animals. To evaluate whether Iba1+ and Iba1-
animals differed in their CEST response, we acquired CEST images covering the frequency
range ± 4 ppm. MTRasym curves differed most in the range< 1ppm. In Iba1+ mice, the MTRa-
sym curve at 0.6 ppm was higher on the side of the LPS administration than in the contralateral
vehicle control region where vehicle was injected (LPS side: 10.7% (interquartile range 10.0–
13.7%); PBS side: 8.2% (interquartile range: 6.6–10.5%; n = 6, p = 0.043 paired t-test, p = 0.094,
Wilcoxon rank sum test; Fig 2). Iba1- mice did not show a significant difference (LPS side:
5.6% (interquartile range 5.2–5.6%); PBS side: 5.9% (interquartile range: 5.1–7.7%; n = 6,
p = 0.88 paired t-test, p = 0.84 Wilcoxon rank sum test). The CEST images in Iba1+ animals
Table 1. Group sizes in analysis.
Response to LPS 1 All WT APP/PS1
Iba1- 6 3 3
Iba1+ 2 6 (4) 3 3 (1)
1 measured by immunohistochemistry. Group sizes after exclusions of animals; two animals reported separately.
2 in two animals, MRS but not CEST measures had to be excluded from further analysis. MRS group sizes shown in
brackets.
https://doi.org/10.1371/journal.pone.0212002.t001
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Fig 1. Microglial activation after LPS immune challenge. (A) Experimental protocol: Animals were anesthetized, injected with LPS and contralaterally
vehicle into the hippocampus, before CEST and MR spectroscopy scans were acquired in a region covering the injection sites. At the end of the experiment,
tissue was processed for histology. (B) Immunohistochemistry: Iba-1 staining revealed stronger microglial activation at the site of the injection (right) in a
subset of animals. Responders to the stimulus (Iba1+, n = 6) had stronger microglial activation on the LPS side compared with an ROI on the contralateral
hemisphere (p< 0.005). This difference was not seen in the other group of animals (Iba1-, n = 6). (C) MR spectroscopy: A typical spectrum (from volumes
delineated in Fig. 1A) is shown on the right with a myoinositol fit curve. There were no significant differences in relative myoinositol levels for either Iba1+
(n = 4, following linewidth exclusions) or Iba1- (n = 6).
https://doi.org/10.1371/journal.pone.0212002.g001
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show a higher CEST signal on the LPS side, but also reveal artefacts in regions of B0 field
inhomogeneities.
Myoinositol levels after LPS. To test whether myoinositol levels in the brain were chang-
ing in response to the inflammatory challenge, we acquired two MR spectroscopy scans, one
centered on the LPS injection site, and one on the contralateral PBS vehicle side (Fig 1 and S1
Fig). While in Iba1+ animals, mI levels relative to tCr on the side of the LPS injection tended
to be higher compared with the contralateral vehicle side, these differences were not significant
(LPS side: 0.82; interquartile range: 0.78–0.84; PBS side: 0.70; interquartile range: 0.69–0.74;
n = 4, p = 0.21, paired t-test, p = 0.38, Wilcoxon rank sum test, n.s.). No significant difference
Fig 2. CEST MR imaging. (A) Mean CEST signal asymmetry (MTRasym) plots for each group (Iba1+, n = 6, and Iba1-, n = 6) from the ROI centered on the
LPS injection site, and the contralateral PBS vehicle. (B) In Iba1+ animals, the CEST signal at 0.6 ppm on the LPS side (LPS Iba1+) was higher than on the
contralateral vehicle side, where vehicle only was injected (PBS Iba1+, n = 6, paired t-test, p< 0.05). The CEST images at 0.6 ppm show the difference between
the hemispheres, but also show artefacts in the lower part of the brain due to B0 inhomogeneity, visible in the B0 maps.
https://doi.org/10.1371/journal.pone.0212002.g002
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between hemispheres was observed in Iba1- animals, where relative mI levels on the LPS side
were 0.64 (interquartile range: 0.60–0.79) and on the PBS side: 0.72 (interquartile range: 0.65–
0.79; n = 6, p = 0.56, paired t-test, p = 0.69, Wilcoxon rank sum test, n.s.). In post-hoc analysis,
we also did not observed significant differences between LPS and vehicle control for glutamate,
glutamine, creatine, or choline.
One animal, a transgenic APPSwe/PS1, did not align with the categorization in Iba1+ vs
Iba1- after LPS administration, but showed more activation on the side where the control vehi-
cle was injected (difference in soma size between LPS vs PBS side -0.15 μm2). In this animal,
mI levels relative to tCr were 0.63 (LPS side) vs 0.63 (PBS side), while CEST MTRasym levels
were 3.96% (LPS side) vs 2.98% (PBS side). In another animal, the injection was performed in
the striatum instead of the hippocampus, with microglia activation present in the LPS side (dif-
ference in soma size between LPS vs PBS side 3.4 μm2). In this animal, mI levels relative to tCr
were 0.61 (LPS side) vs 0.51 (PBS side), while CEST MTRasym levels were 6.3% (LPS side) vs
4.7% (PBS side).
Discussion
In this pilot study, we used intracerebral low dose LPS as an acute inflammation challenge in
young wild type and AD mice. We designed the pilot study to explore whether CEST can
index activation of microglia with this inflammatory challenge, and whether at these early
stages of disease, MRS and CEST biomarkers would be sensitive enough to distinguish differ-
ential levels, if present, of activation in WT and AD animals. While an LPS challenge is an
established procedure, we found the immune response at this dose to be highly variable; unilat-
eral activation of microglia was seen by immunohistochemistry only in a subset of animals
(‘Iba1+’).
To test whether CEST MRI could be a specific imaging biomarker to monitor the inflam-
matory response, we chose an LPS challenge as one of the more widely used experimental
routes of inducing neuroinflammation [45]. A lipopolysaccharide challenge is of particular
interest in Alzheimer’s disease, since LPS may impact hallmarks of disease in mouse models of
AD. Intrahippocampal LPS injections have been shown to reduce β-amyloid peptide load in
transgenic AD mouse model mice [46]. Also, the LPS-derived TLR-4 ligand monophosphoryl
lipid A (MPL) restricts cognitive deficits in APP/PS1 transgenic mice [47]. Moreover, LPS
induces a stronger inflammatory response in AD model mice than in wild type controls [48].
We chose a direct injection into the hippocampus to allow intra-subject comparisons, and due
to the poor brain penetration of LPS [28]. We chose the low dose of LPS based on our earlier
in vivo study, where we sought to elicit a differential response between WT and AD mice [21].
Specifically, we had found that peripheral, low dose (100 μg/kg) LPS led to a significant
increase in myoinositol levels within four hours in the AD transgenic mice but not in WT con-
trols. Consequently, in the current study we had expected that the direct intracerebral chal-
lenge would lead to differential levels of microglial activation in the AD model where primed
microglia may be more susceptible. However, while a subset of animals showed a pronounced
response to LPS readily identifiable in immunohistochemistry, this variation did not align
with genotype. A possible explanation could be that at this young age, differences between
genotypes are not very significant, since for example, this model only starts to show synaptic
loss by 4 months, and plaques and gliosis by around 6 months [49].
Therefore, rather than separating the groups for analysis in WT and AD, instead we
grouped animals based on whether a unilateral activation was observed (Iba1+ vs non Iba1-),
by an expert blind to the study examining the slides from immunohistochemistry stained for
the microglial marker protein Iba-1. The assessment by the pathologist served as the gold
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standard for separating the groups, and this did align with the difference in soma size as a
quantitative measure between the two groups. Soma size was the measure we used in our pre-
vious study as a marker of microglia activation, although more accurate histological measures
would allow to determine the presence of neuroinflammation. There is a linear, albeit weak
relationship between the CEST signal and the quantitative histology measures, when consider-
ing the difference between the LPS injection site and the contralateral vehicle control (S3 Fig).
In those animals, where an acute intracerebral LPS challenge led to a pronounced micro-
glial response, the CEST MRI signal at 0.6 ppm was higher in the brain hemisphere where LPS
was injected, compared with the contralateral control with vehicle injection only. In our pilot
study, myoinositol levels measured by MR spectroscopy tended to be higher following LPS but
did not reach significance. A possible explanation is the smaller group size with MRS data,
compared to histology and CEST. Two MRS datasets from the Iba1+ group had to be excluded
due to the spectral quality (linewidth criteria).
A range of in vivo imaging techniques based on PET or MRI have been proposed to study
neuroinflammation and its spatial distribution. PET imaging of the TSPO receptor is the best
characterized translational technique for imaging neuroinflammation in vivo. MR contrast
agents have been widely used to visualize local inflammation in the brain, for example with
superparamagnetic iron oxide particles [50] or with perfluorocarbons [51], which avoids back-
ground signal but lacks sensitivity. More targeted approaches to image neuroinflammation
have been successful with contrast agents, for example dextran coated SPIOs, functionalized
with antibodies or ligands that bind to specific targets [52]. An endogenous MR imaging bio-
marker that is sensitive and specific enough to detect LPS induced metabolic changes with
high spatial resolution would be an important step, because once validated it could be readily
transferred to clinical MR systems. Microstructural changes as a consequence of local neuroin-
flammation have been assessed with diffusion MRI [53] or magnetization transfer imaging
[54], but these approaches still lack specificity. A range of studies have assessed spectroscopic
changes [9] at the expense of spatial resolution. CEST MRI has the potential to bridge this gap,
targeting specific moieties while retaining spatial resolution. However, care must be taken
when interpreting our results, because of challenges due to the model and the CEST contrast
itself.
Hydroxyl groups have broad CEST effects in the 0–1.5 ppm region. Other visible contribu-
tions to the CEST spectrum in our data are the amine (2 ppm) and amine (3.5 ppm) peaks.
The peak at 2 ppm is generally attributed to creatine [55] and proteins [56], but did not differ
between groups that showed a more pronounced response to LPS (‘Iba1+’). CEST MRI in the
frequency range below 1 ppm poses several technical challenges. First, CEST resonances from
hydroxyl groups are strongly affected by direct water saturation since both the CEST effect and
spillover or direct saturation of the free water pool increase with B1 power. Direct saturation
thus imposes a restriction on the RF pulse power and limits the CEST saturation efficiency.
Secondly, static magnetic field (B0) inhomogeneities shift the water resonance frequency,
which results in asymmetric direct water saturation and consequently in artefacts in asymme-
try analysis. The sharp peak at ~ 0.2 ppm (vehicle control–Iba1- group) is a B0 artifact. Accu-
rate correction of field inhomogeneities is crucial for CEST asymmetry measurements. After
extensive shimming before each MR measurement, we used the WASSR method to map the
water frequency. However, there are still changes in susceptibility in regions of tissue—air
interface. We therefore filled the space between the top of the head and the volume coil with
agarose to reduce susceptibility artifacts and reduce variability (S4 Fig). We only quantified
CEST changes if a sufficient B0 field homogeneity across both regions of interest in the
hippocampus was achieved. Many groups studying the APT (amide proton transfer, around
3.5 ppm) signal are using Lorentzian fitting methods [57, 58], mainly because of asymmetric
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magnetization transfer (MT) effects around the water peak. Asymmetric MT does not have a
significant effect on the CEST contrast for frequency offsets close to the water peak. Further-
more, in cases where CEST pool line shapes have merged with that of water (as in the case of
hydroxyl groups), the line shape is not Lorentzian anymore and fitting will fail [59]. Hence
asymmetry analysis is most suited to our analysis even though it does not allow to extract sub-
tle details of the signal.
We cannot simply attribute the inflammatory response to the impact of LPS, because a
range of factors contribute to the inflammatory response and the signals measured by MR
spectroscopy and CEST MRI. The high variability we observed in microglia activity (Iba-1)
could be caused by differences in the efficiency of LPS delivery between experimenters, brain
injury during injection, or for example the drug viability over time (see S1 Table). To avoid
bias, we therefore based our analysis and interpretation on the resulting Iba1 activity as the
starting point.
An intrinsic complication for the interpretation of the CEST signal is the overlap of differ-
ent molecules in the region of the myoinositol resonance. Several groups demonstrated how
metabolites that contribute to the CEST signal overlap, including glutamate, glutamine, crea-
tine, taurine and many endogenous molecules contain exchangeable–OH therefore potentially
contributing to the total CEST signal (e.g. glucose, choline and myoinositol, glycerophospho-
choline, and glycoproteins) [57, 60–62], an effect that we also reproduced here (S5 Fig). There-
fore, direct attribution of the observed CEST effect to a specific metabolite change would
require completely isolating this from other contributions, which is difficult when studying the
cascade of molecular events involved in inflammation. In our study, we measured in addition
to myoinositol a range of metabolites that overlap with the CEST signal < 1ppm, but did not
find any significant changes after the LPS challenge. We did also exclude an effect of the drug
molecule itself on the CEST signal (S5 Fig).
The injury caused by vehicle injection into the brain alone will cause a degree of microglial
activation and injection sites were visible in T2 maps (but not in T2 weighted images), although
signal levels in T2 maps did not differ between LPS and vehicle (S2 Fig). In our experiment, we
controlled the effect of the injection with contralateral vehicle administration, but this does
not isolate the effect of LPS.
An improvement of the current protocol may be to acquire CEST MRI and MRS separately
before and after each injection (LPS and vehicle). This would allow a more careful distinction
of the effects of the intervention and allow to separate the effect of LPS and injection, but
require a setup where LPS and vehicle are administered in the scanner rather than the
approach chosen here where procedures are separated.
It is also important to note that the area of microglial activation in histology does not pre-
cisely fit an outline of the area of higher signal in CEST MRI. This may be due to the difficulties
in clearly delineating LPS enhancement or the CEST threshold chosen, but also to differences
in the volume covered by the different techniques. For the quantitative assessment of our
CEST MRI images and the histology, we chose a region of interest centered on the target of the
injection, which was the same size in the image plane but differed in the slice thickness (2 mm
for CEST, 7 μm for histology). However, the distinction into Iba1+ and Iba1- was based on the
qualitative assessment of the pathologist.
We had hypothesized that a change in the CEST signal would be accompanied by an
increase in the levels of myoinositol measured by MRS. In the group of animals responding
strongly to LPS, myoinositol levels tended to be higher after LPS but did not reach significance.
We also tested, post-hoc, other potential inflammation markers, including glutamate, choline
and creatine, but these did not show significant differences. We had expected a myoinositol
increase, since in contrast to our earlier study with peripheral LPS administration, we opted
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for the direct LPS challenge, where initial scans suggested the change in myoinositol levels.
Our study does not in itself really clarify the role of myoinositol as an MRS biomarker for neu-
roinflammation, partially due to the limited size of our pilot study. We initially chose myoino-
sitol due to the number of studies pointing to its potential to index neuroinflammation, but
recent work from our group and others question a direct link to microglial activation [16, 17,
22, 23]. Datta et al. [25] reported that MRS determined myoinositol levels were not associated
with TSPO PET in patients with Multiple Sclerosis. The authors suggested that both measures
might be related to the same common process but with different time courses, or to different
processes, with histopathology results suggesting a link between myoinositol and astrocyte
activation.
Future experiments could benefit from another inflammatory model. Sauvage et al. locally
induced astrocytic activation through lateral injection of lentiviral vectors encoding either the
human CNTF gene or the β-galactosidase gene as control [14]. This is a very robust challenge
which may not be representative of neuroinflammation occurring in early stages of disease,
but a similar approach may be feasible that is selective for microglia. Further validation will
also be necessary, for example with another imaging modality such as with TSPO PET, or the
suppression of the inflammatory response with minocycline [63].
In terms of acquisition, a chemical exchange-sensitive spin lock type of experiment (higher
power and shorter irradiation) would increase the sensitivity to faster exchanging spins (such
as hydroxyls), while minimizing the influence of slower exchanging spins [64]. While CEST
MRI benefits from higher magnetic field strength, there is potential for hydroxyl CEST in the
clinic, with recent work showing that variable saturation amplitude CEST can improve sensi-
tivity at 3T [65].
Conclusion
In this study, we set out to monitor the response to LPS as an inflammatory stimulus with
CEST. Our data suggests that CEST MRI in the hydroxyl region is sensitive to the effect of a
low dose LPS inflammatory challenge in mice that show a pronounced microglial response.
The immune response to LPS was highly variable and did not align with genotype. This may
be due to the variability in the response to the intracerebral LPS injection, or the young age of
the animals (3 months old), which may be too early to detect differences between genotypes.
The sensitivity of CEST could not be explained by changes in myoinositol levels measured by
MR spectroscopy, even though they tended to be higher. If a sufficiently sensitive CEST mea-
sure for neuroinflammation could be established on a clinical scanner, it could have important
implications for drug development and early diagnosis in neurodegenerative disorders.
Supporting information
S1 Table. Details of experiment and resulting classification into iba1+ animals (respond-
ers) or Iba1—Non-responders, with contributing factors experimenter and genotype). In
highlighted animals, there was at least a 20% change in CEST signal between LPS and PBS
side.
(PDF)
S1 Fig. Response to LPS. Histology was used to divide animals into Iba1+ and Iba1- to the
LPS intervention. Shown here are a larger view of an example histology slide (A) with the cor-
responding CEST signal (B) for an Iba1+ animal with higher levels of microglial response on
the LPS injection site, compared with the contralateral vehicle injection site.
(EPS)
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S2 Fig. T2 weighted images. T2 weighted images were acquired for all animals, while T2 maps
were acquired for a subset of n = 6 animals. A) Representative T2 weighted image, with no visi-
ble effect from the injections (edema or hemorrhage). B) Both injections were visible in T2
maps (increased contrast in injection sites), however T2 values did not differ significantly
between the LPS vs vehicle injection site.
(EPS)
S3 Fig. Quantitative histology measures vs CEST signal. In addition to the classification into
Iba1+ and Iba1-, which was based on the judgement of an experienced pathologist, we corre-
lated a quantitative, morphometric marker of microglia activation (soma size) with the CEST
response. The difference between the LPS injection side and the contralateral vehicle control
(LPS side–PBS vehicle side) showed a weak relation to the CEST signal difference.
(EPS)
S4 Fig. CEST signal variability in control animals. To improve field homogeneity, we applied
a gel cap to the top of the skull, which improved B0 homogeneity across the brain: (A) After
shimming but without gel cap the B0 map, CEST map and the asymmetry spectrum from an
ROI on the hippocampus; (B) with the 3% agarose gel cap. The CEST spectrum showed less
artifacts close to the water peak. C) CEST measurements at 0.6 ppm were acquired in four wild
type mice in the absence of any intervention and averaged across ROIs in the left and right hip-
pocampus. CEST MTRasym at 0.6 ppm were not significantly different between right and left
side: in the left hippocampus ROI the CEST signal median was 7.6% (6.2%– 8.8%), while in
the right hippocampus ROI the median was 6.6% (6.3% - 6.8%, n = 4, n.s.).
(EPS)
S5 Fig. Contribution of different metabolites to CEST signal. While the drug (LPS) itself
does not have a measurable effect in the CEST MRI acquisition, several metabolites overlap
and contribute to the CEST effect around 0.6 ppm. (A) Z spectrum and asymmetry spectrum
of LPS in saline solution (5ng/μL concentration, pH 7.4). (B) Z-spectrum of several brain
metabolites containing -OH groups in saline solution, at physiological concentrations (crea-
tine 6 mM, myo-inositol 6mM, glutamate 12mM, D-glucose 4mM, glutamine 4mM, GABA
3mM).
(EPS)
Acknowledgments
We acknowledge support on interpretation of histology from Diana Cash and Camilla Sim-
mons, BRAIN Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London.
We also thank Dr Nicoleta Baxan (Biological Imaging Centre, Imperial College London)
for assistance with acquiring the in vitro CEST MRI data.
Author Contributions
Conceptualization: Marie-Christine Pardon, Dorothee P. Auer, Henryk M. Faas.
Data curation: Marie-Christine Pardon, Henryk M. Faas.
Formal analysis: Maria Yanez Lopez, Kerstin Baiker, Henryk M. Faas.
Funding acquisition: Henryk M. Faas.
Investigation: Malcolm Prior, Alessandra Agostini.
Monitoring the response to LPS with CEST MR imaging
PLOS ONE | https://doi.org/10.1371/journal.pone.0212002 February 21, 2019 14 / 18
Methodology: Maria Yanez Lopez, Marie-Christine Pardon, Li Bai, Henryk M. Faas.
Project administration: Henryk M. Faas.
Software: Maria Yanez Lopez, Ding Yuchun, Li Bai.
Supervision: Li Bai, Henryk M. Faas.
Validation: Maria Yanez Lopez, Kerstin Baiker, Dorothee P. Auer, Henryk M. Faas.
Writing – original draft: Maria Yanez Lopez, Henryk M. Faas.
Writing – review & editing: Marie-Christine Pardon, Kerstin Baiker, Dorothee P. Auer, Hen-
ryk M. Faas.
References
1. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflamma-
tion in Alzheimer’s disease. Lancet Neurol. 2015; 14(4):388–405. https://doi.org/10.1016/S1474-4422
(15)70016-5 PMID: 25792098.
2. Stefaniak J, O’Brien J. Imaging of neuroinflammation in dementia: a review. J Neurol Neurosurg Psychi-
atry. 2016; 87(1):21–8. https://doi.org/10.1136/jnnp-2015-311336 PMID: 26384512.
3. Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, et al. T cells from patients with Parkin-
son’s disease recognize alpha-synuclein peptides. Nature. 2017; 546(7660):656–61. https://doi.org/10.
1038/nature22815 PMID: 28636593.
4. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev
Immunol. 2009; 27:119–45. https://doi.org/10.1146/annurev.immunol.021908.132528 PMID:
19302036.
5. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin chal-
lenges exacerbate the local inflammatory response and increase neuronal death during chronic neuro-
degeneration. J Neurosci. 2005; 25(40):9275–84. https://doi.org/10.1523/JNEUROSCI.2614-05.2005
PMID: 16207887.
6. Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;
339(6116):156–61. https://doi.org/10.1126/science.1227901 PMID: 23307732.
7. Suridjan I, Rusjan PM, Voineskos AN, Selvanathan T, Setiawan E, Strafella AP, et al. Neuroinflamma-
tion in healthy aging: a PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [(18)
F]-FEPPA. NeuroImage. 2014; 84:868–75. https://doi.org/10.1016/j.neuroimage.2013.09.021 PMID:
24064066.
8. Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A, et al. The method-
ology of TSPO imaging with positron emission tomography. Biochemical Society transactions. 2015;
43(4):586–92. https://doi.org/10.1042/BST20150058 PMID: 26551697.
9. Chang L, Munsaka SM, Kraft-Terry S, Ernst T. Magnetic resonance spectroscopy to assess neuroin-
flammation and neuropathic pain. Journal of neuroimmune pharmacology: the official journal of the
Society on NeuroImmune Pharmacology. 2013; 8(3):576–93. https://doi.org/10.1007/s11481-013-
9460-x PMID: 23666436.
10. Schneider P, Weber-Fahr W, Schweinfurth N, Ho YJ, Sartorius A, Spanagel R, et al. Central metabolite
changes and activation of microglia after peripheral interleukin-2 challenge. Brain, behavior, and immu-
nity. 2012; 26(2):277–83. https://doi.org/10.1016/j.bbi.2011.09.011 PMID: 21983278.
11. Zahr NM, Mayer D, Rohlfing T, Sullivan EV, Pfefferbaum A. Imaging neuroinflammation? A perspective
from MR spectroscopy. Brain Pathol. 2014; 24(6):654–64. https://doi.org/10.1111/bpa.12197 PMID:
25345895.
12. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical
exchange dependent saturation transfer (CEST). Journal of magnetic resonance. 2000; 143(1):79–87.
https://doi.org/10.1006/jmre.1999.1956 PMID: 10698648.
13. Haris M, Nath K, Cai K, Singh A, Crescenzi R, Kogan F, et al. Imaging of glutamate neurotransmitter
alterations in Alzheimer’s disease. NMR in biomedicine. 2013; 26(4):386–91. https://doi.org/10.1002/
nbm.2875 PMID: 23045158.
14. Carrillo-de Sauvage MA, Flament J, Bramoulle Y, Ben Haim L, Guillermier M, Berniard A, et al. The neu-
roprotective agent CNTF decreases neuronal metabolites in the rat striatum: an in vivo multimodal mag-
netic resonance imaging study. Journal of cerebral blood flow and metabolism: official journal of the
Monitoring the response to LPS with CEST MR imaging
PLOS ONE | https://doi.org/10.1371/journal.pone.0212002 February 21, 2019 15 / 18
International Society of Cerebral Blood Flow and Metabolism. 2015; 35(6):917–21. https://doi.org/10.
1038/jcbfm.2015.48 PMID: 25833344.
15. Wells JA, O’Callaghan JM, Holmes HE, Powell NM, Johnson RA, Siow B, et al. In vivo imaging of tau
pathology using multi-parametric quantitative MRI. NeuroImage. 2015; 111:369–78. https://doi.org/10.
1016/j.neuroimage.2015.02.023 PMID: 25700953.
16. Pepin J, Francelle L, Carrillo-de Sauvage MA, de Longprez L, Gipchtein P, Cambon K, et al. In vivo
imaging of brain glutamate defects in a knock-in mouse model of Huntington’s disease. NeuroImage.
2016; 139:53–64. https://doi.org/10.1016/j.neuroimage.2016.06.023 PMID: 27318215.
17. Roalf DR, Nanga RP, Rupert PE, Hariharan H, Quarmley M, Calkins ME, et al. Glutamate imaging (Glu-
CEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrum. Molecular psychia-
try. 2017. https://doi.org/10.1038/mp.2016.258 PMID: 28115738.
18. Bagga P, Crescenzi R, Krishnamoorthy G, Verma G, Nanga RP, Reddy D, et al. Mapping the alterations
in glutamate with GluCEST MRI in a mouse model of dopamine deficiency. J Neurochem. 2016; 139
(3):432–9. https://doi.org/10.1111/jnc.13771 PMID: 27529288.
19. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial
and neuronal cells. Developmental neuroscience. 1993; 15(3–5):289–98. https://doi.org/10.1159/
000111347 PMID: 7805581.
20. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, et al. Inflammatory CNS demye-
lination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neu-
roradiol. 1999; 20(9):1619–27. PMID: 10543631.
21. Pardon MC, Yanez Lopez M, Yuchun D, Marjanska M, Prior M, Brignell C, et al. Magnetic Resonance
Spectroscopy discriminates the response to microglial stimulation of wild type and Alzheimer’s disease
models. Scientific reports. 2016; 6:19880. https://doi.org/10.1038/srep19880 PMID: 26813748.
22. Murray ME, Przybelski SA, Lesnick TG, Liesinger AM, Spychalla A, Zhang B, et al. Early Alzheimer’s
disease neuropathology detected by proton MR spectroscopy. J Neurosci. 2014; 34(49):16247–55.
https://doi.org/10.1523/JNEUROSCI.2027-14.2014 PMID: 25471565.
23. Haris M, Cai K, Singh A, Hariharan H, Reddy R. In vivo mapping of brain myo-inositol. NeuroImage.
2011; 54(3):2079–85. https://doi.org/10.1016/j.neuroimage.2010.10.017 PMID: 20951217.
24. Huang W, Alexander GE, Daly EM, Shetty HU, Krasuski JS, Rapoport SI, et al. High brain myo-inositol
levels in the predementia phase of Alzheimer’s disease in adults with Down’s syndrome: a 1H MRS
study. Am J Psychiatry. 1999; 156(12):1879–86. PMID: 10588400.
25. Datta G, Violante IR, Scott G, Zimmerman K, Santos-Ribeiro A, Rabiner EA, et al. Translocator posi-
tron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation
in multiple sclerosis. Mult Scler. 2016:1352458516681504. https://doi.org/10.1177/1352458516681504
PMID: 27903933.
26. Marjanska M, Weigand SD, Preboske G, Wengenack TM, Chamberlain R, Curran GL, et al. Treatment
effects in a transgenic mouse model of Alzheimer’s disease: a magnetic resonance spectroscopy study
after passive immunization. Neuroscience. 2014; 259:94–100. https://doi.org/10.1016/j.neuroscience.
2013.11.052 PMID: 24316473.
27. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipo-
polysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci. 2000; 20(16):6309–
16. PMID: 10934283.
28. Banks WA, Robinson SM. Minimal penetration of lipopolysaccharide across the murine blood-brain bar-
rier. Brain, behavior, and immunity. 2010; 24(1):102–9. https://doi.org/10.1016/j.bbi.2009.09.001 PMID:
19735725.
29. Liu G, Bettegowda C, Qiao Y, Staedtke V, Chan KW, Bai R, et al. Noninvasive imaging of infection after
treatment with tumor-homing bacteria using Chemical Exchange Saturation Transfer (CEST) MRI.
Magnetic resonance in medicine. 2013; 70(6):1690–8. https://doi.org/10.1002/mrm.24955 PMID:
24123389.
30. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting:
the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010; 8(6):e1000412. https://doi.org/
10.1371/journal.pbio.1000412 PMID: 20613859.
31. Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magnetic reso-
nance in medicine. 1986; 3(6):823–33. PMID: 3821461.
32. Gruetter R. Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magnetic
resonance in medicine. 1993; 29(6):804–11. PMID: 8350724.
33. Garwood M, DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contempo-
rary NMR. Journal of magnetic resonance. 2001; 153(2):155–77. https://doi.org/10.1006/jmre.2001.
2340 PMID: 11740891.
Monitoring the response to LPS with CEST MR imaging
PLOS ONE | https://doi.org/10.1371/journal.pone.0212002 February 21, 2019 16 / 18
34. Tkac I, Starcuk Z, Choi IY, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time.
Magnetic resonance in medicine. 1999; 41(4):649–56. PMID: 10332839.
35. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra.
Magnetic resonance in medicine. 1993; 30(6):672–9. PMID: 8139448.
36. Kim M, Gillen J, Landman BA, Zhou J, van Zijl PC. Water saturation shift referencing (WASSR) for
chemical exchange saturation transfer (CEST) experiments. Magnetic resonance in medicine. 2009;
61(6):1441–50. https://doi.org/10.1002/mrm.21873 PMID: 19358232.
37. Woessner DE, Zhang S, Merritt ME, Sherry AD. Numerical solution of the Bloch equations provides
insights into the optimum design of PARACEST agents for MRI. Magnetic resonance in medicine.
2005; 53(4):790–9. https://doi.org/10.1002/mrm.20408 PMID: 15799055.
38. Henkelman RM, Huang X, Xiang QS, Stanisz GJ, Swanson SD, Bronskill MJ. Quantitative interpretation
of magnetization transfer. Magnetic resonance in medicine. 1993; 29(6):759–66. PMID: 8350718.
39. Sled JG, Pike GB. Quantitative imaging of magnetization transfer exchange and relaxation properties in
vivo using MRI. Magnetic resonance in medicine. 2001; 46(5):923–31. PMID: 11675644.
40. Adamczak JM, Farr TD, Seehafer JU, Kalthoff D, Hoehn M. High field BOLD response to forepaw stimu-
lation in the mouse. NeuroImage. 2010; 51(2):704–12. https://doi.org/10.1016/j.neuroimage.2010.02.
083 PMID: 20211267.
41. Ding Y, Pardon MC, Agostini A, Faas H, Duan J, Ward WO, et al. Novel Methods for Microglia Segmen-
tation, Feature Extraction and Classification. IEEE/ACM Trans Comput Biol Bioinform. 2016. https://doi.
org/10.1109/TCBB.2016.2591520 PMID: 27429441.
42. Kozlowski C, Weimer RM. An automated method to quantify microglia morphology and application to
monitor activation state longitudinally in vivo. PloS one. 2012; 7(2):e31814. https://doi.org/10.1371/
journal.pone.0031814 PMID: 22457705.
43. Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV, et al. Dynamic microglial
alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Molecular
psychiatry. 2014; 19(6):699–709. https://doi.org/10.1038/mp.2013.155 PMID: 24342992.
44. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Com-
puting, Vienna, Austria. 2013.
45. Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, et al. Time-dependent reduction in
Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol. 2004; 190
(1):245–53. https://doi.org/10.1016/j.expneurol.2004.07.007 PMID: 15473997.
46. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce
Abeta load in APP+PS1 transgenic mice. Neurobiol Aging. 2001; 22(6):1007–12. PMID: 11755009.
47. Michaud JP, Halle M, Lampron A, Theriault P, Prefontaine P, Filali M, et al. Toll-like receptor 4 stimula-
tion with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology.
Proc Natl Acad Sci U S A. 2013; 110(5):1941–6. https://doi.org/10.1073/pnas.1215165110 PMID:
23322736.
48. Go M, Kou J, Lim JE, Yang J, Fukuchi KI. Microglial response to LPS increases in wild-type mice during
aging but diminishes in an Alzheimer’s mouse model: Implication of TLR4 signaling in disease progres-
sion. Biochem Biophys Res Commun. 2016; 479(2):331–7. https://doi.org/10.1016/j.bbrc.2016.09.073
PMID: 27641666.
49. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins spe-
cifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a
42-specific gamma secretase. Hum Mol Genet. 2004; 13(2):159–70. https://doi.org/10.1093/hmg/
ddh019 PMID: 14645205.
50. Robinson KM, Njus JM, Phillips DA, Proctor TM, Rooney WD, Jones RE. MR imaging of inflammation
during myelin-specific T cell-mediated autoimmune attack in the EAE mouse spinal cord. Mol Imaging
Biol. 2010; 12(3):240–9. https://doi.org/10.1007/s11307-009-0272-6 PMID: 19949987.
51. Zhong J, Narsinh K, Morel PA, Xu H, Ahrens ET. In Vivo Quantification of Inflammation in Experimental
Autoimmune Encephalomyelitis Rats Using Fluorine-19 Magnetic Resonance Imaging Reveals
Immune Cell Recruitment outside the Nervous System. PloS one. 2015; 10(10):e0140238. https://doi.
org/10.1371/journal.pone.0140238 PMID: 26485716.
52. McAteer MA, Sibson NR, von Zur Muhlen C, Schneider JE, Lowe AS, Warrick N, et al. In vivo magnetic
resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med. 2007; 13
(10):1253–8. https://doi.org/10.1038/nm1631 PMID: 17891147.
53. Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, et al. Cerebrospinal Fluid Mark-
ers of Alzheimer’s Disease Pathology and Microglial Activation are Associated with Altered White Mat-
ter Microstructure in Asymptomatic Adults at Risk for Alzheimer’s Disease. J Alzheimers Dis. 2016; 50
(3):873–86. https://doi.org/10.3233/JAD-150897 PMID: 26836182.
Monitoring the response to LPS with CEST MR imaging
PLOS ONE | https://doi.org/10.1371/journal.pone.0212002 February 21, 2019 17 / 18
54. Liu Z, Pardini M, Yaldizli O, Sethi V, Muhlert N, Wheeler-Kingshott CA, et al. Magnetization transfer
ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple
sclerosis. Brain. 2015; 138(Pt 5):1239–46. https://doi.org/10.1093/brain/awv065 PMID: 25823475.
55. Cai K, Singh A, Poptani H, Li W, Yang S, Lu Y, et al. CEST signal at 2ppm (CEST@2ppm) from Z-spec-
tral fitting correlates with creatine distribution in brain tumor. NMR in biomedicine. 2015; 28(1):1–8.
https://doi.org/10.1002/nbm.3216 PMID: 25295758.
56. Zhang XY, Xie J, Wang F, Lin EC, Xu J, Gochberg DF, et al. Assignment of the molecular origins of
CEST signals at 2 ppm in rat brain. Magnetic resonance in medicine. 2017; 78(3):881–7. https://doi.org/
10.1002/mrm.26802 PMID: 28653349.
57. Lee JS, Xia D, Jerschow A, Regatte RR. In vitro study of endogenous CEST agents at 3 T and 7 T. Con-
trast media & molecular imaging. 2016; 11(1):4–14. https://doi.org/10.1002/cmmi.1652 PMID:
26153196.
58. Lee DH, Heo HY, Zhang K, Zhang Y, Jiang S, Zhao X, et al. Quantitative assessment of the effects of
water proton concentration and water T changes on amide proton transfer (APT) and nuclear overhau-
ser enhancement (NOE) MRI: The origin of the APT imaging signal in brain tumor. Magnetic resonance
in medicine. 2016. https://doi.org/10.1002/mrm.26131 PMID: 26841096.
59. Zhang XY, Wang F, Li H, Xu J, Gochberg DF, Gore JC, et al. Accuracy in the quantification of chemical
exchange saturation transfer (CEST) and relayed nuclear Overhauser enhancement (rNOE) saturation
transfer effects. NMR in biomedicine. 2017;30(7). https://doi.org/10.1002/nbm.3716 PMID: 28272761.
60. Tu TW, Ibrahim WG, Jikaria N, Munasinghe JP, Witko JA, Hammoud DA, et al. On the detection of cere-
bral metabolic depression in experimental traumatic brain injury using Chemical Exchange Saturation
Transfer (CEST)-weighted MRI. Scientific reports. 2018; 8(1):669. https://doi.org/10.1038/s41598-017-
19094-z PMID: 29330386.
61. Chan KW, Jiang L, Cheng M, Wijnen JP, Liu G, Huang P, et al. CEST-MRI detects metabolite levels
altered by breast cancer cell aggressiveness and chemotherapy response. NMR in biomedicine. 2016;
29(6):806–16. https://doi.org/10.1002/nbm.3526 PMID: 27100284.
62. Song X, Airan RD, Arifin DR, Bar-Shir A, Kadayakkara DK, Liu G, et al. Label-free in vivo molecular
imaging of underglycosylated mucin-1 expression in tumour cells. Nat Commun. 2015; 6:6719. https://
doi.org/10.1038/ncomms7719 PMID: 25813863.
63. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. Minocycline attenuates lipopolysac-
charide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation.
2008; 5:15. https://doi.org/10.1186/1742-2094-5-15 PMID: 18477398.
64. Jin T, Kim SG. Advantages of chemical exchange-sensitive spin-lock (CESL) over chemical exchange
saturation transfer (CEST) for hydroxyl- and amine-water proton exchange studies. NMR in biomedi-
cine. 2014; 27(11):1313–24. https://doi.org/10.1002/nbm.3191 PMID: 25199631.
65. Clark DJ, Smith AK, Dortch RD, Knopp MV, Smith SA. Investigating hydroxyl chemical exchange using
a variable saturation power chemical exchange saturation transfer (vCEST) method at 3 T. Magnetic
resonance in medicine. 2016; 76(3):826–37. https://doi.org/10.1002/mrm.25987 PMID: 26414937.
Monitoring the response to LPS with CEST MR imaging
PLOS ONE | https://doi.org/10.1371/journal.pone.0212002 February 21, 2019 18 / 18
